Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Mayo researchers to announce new findings about promising early-stage breast cancer treatment

17.05.2005


NCCTG investigations yield additional significant data



A study led by a Mayo Clinic medical oncologist and conducted by the North Central Cancer Treatment Group (NCCTG) provides important new data about the effectiveness and safety of a breast cancer treatment combining chemotherapy and a drug called trastuzumab (Herceptin).

According to Mayo Clinic medical oncologist and NCCTG study chair Edith Perez, M.D., these results could change the standard of care for thousands of women with breast cancer. "Women with HER-2 positive breast cancer had a high risk of the cancer returning and of dying from breast cancer. This intervention -- chemotherapy plus trastuzumab -- essentially changes the natural history of the disease," says Dr. Perez.


The National Cancer Institute (NCI) sponsored two large, multicenter clinical trials studying more than 3,300 women with breast cancer between February 2000 and April 2005. These two Phase III trials were conducted by NCCTG and the National Surgical Adjuvant Breast and Bowel Project (NSABP), in collaboration with other research groups throughout the United States.

Dr. Perez, from Mayo Clinic in Jacksonville, Fla., will report results from the NCCTG trial (N9831) on Monday, May 16, at the 2005 American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Fla.

The NCCTG trial is the only study that will offer new data comparing whether trastuzumab is more effective in preventing recurrence when it’s given during (concurrently) or after (sequentially) chemotherapy. These findings will be important tools to help oncologists determine how to optimize trastuzumab’s protective effect in the course of treating patients with HER-2 positive breast cancer.

"Our preliminary data show that sequential treatment is good, but trastuzumab given concurrently with chemotherapy yielded important trends for better results. Although longer follow-up is needed, this difference led to the recommendation that study participants who are currently receiving chemotherapy should receive trastuzumab at the same time as the paclitaxel, instead of waiting," says Dr. Perez.

Lee Aase | EurekAlert!
Further information:
http://www.mayo.edu
http://www.mayoclinic.com

More articles from Studies and Analyses:

nachricht WAKE-UP provides new treatment option for stroke patients | International study led by UKE
17.05.2018 | Universitätsklinikum Hamburg-Eppendorf

nachricht First form of therapy for childhood dementia CLN2 developed
25.04.2018 | Universitätsklinikum Hamburg-Eppendorf

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: LZH showcases laser material processing of tomorrow at the LASYS 2018

At the LASYS 2018, from June 5th to 7th, the Laser Zentrum Hannover e.V. (LZH) will be showcasing processes for the laser material processing of tomorrow in hall 4 at stand 4E75. With blown bomb shells the LZH will present first results of a research project on civil security.

At this year's LASYS, the LZH will exhibit light-based processes such as cutting, welding, ablation and structuring as well as additive manufacturing for...

Im Focus: Self-illuminating pixels for a new display generation

There are videos on the internet that can make one marvel at technology. For example, a smartphone is casually bent around the arm or a thin-film display is rolled in all directions and with almost every diameter. From the user's point of view, this looks fantastic. From a professional point of view, however, the question arises: Is that already possible?

At Display Week 2018, scientists from the Fraunhofer Institute for Applied Polymer Research IAP will be demonstrating today’s technological possibilities and...

Im Focus: Explanation for puzzling quantum oscillations has been found

So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics

Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...

Im Focus: Dozens of binaries from Milky Way's globular clusters could be detectable by LISA

Next-generation gravitational wave detector in space will complement LIGO on Earth

The historic first detection of gravitational waves from colliding black holes far outside our galaxy opened a new window to understanding the universe. A...

Im Focus: Entangled atoms shine in unison

A team led by Austrian experimental physicist Rainer Blatt has succeeded in characterizing the quantum entanglement of two spatially separated atoms by observing their light emission. This fundamental demonstration could lead to the development of highly sensitive optical gradiometers for the precise measurement of the gravitational field or the earth's magnetic field.

The age of quantum technology has long been heralded. Decades of research into the quantum world have led to the development of methods that make it possible...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Save the date: Forum European Neuroscience – 07-11 July 2018 in Berlin, Germany

02.05.2018 | Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

Unique scope of UV LED technologies and applications presented in Berlin: ICULTA-2018

12.04.2018 | Event News

 
Latest News

Research reveals how order first appears in liquid crystals

23.05.2018 | Life Sciences

Space-like gravity weakens biochemical signals in muscle formation

23.05.2018 | Life Sciences

NIST puts the optical microscope under the microscope to achieve atomic accuracy

23.05.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>